Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities

Fig. 6

Immunohistochemical analysis of LYVE-1 and TUNEL assay in vivo. Sections from vehicle group and 150 mg/kg YL529-treated tumor were collected. (a) LYVE-1 and (b) TUNEL were detected in the VEGF-D-LL/2 tumor model. Quantitative of the mean LYVE-1 and TUNEL-positive area counted at × 200. Mean ± SEM, 200×, n = 6, *p < 0.05, **p < 0.01

Back to article page